Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-06
2007-03-06
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S252100, C514S253010, C544S122000, C544S298000, C544S360000, C546S191000
Reexamination Certificate
active
09922631
ABSTRACT:
Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
REFERENCES:
patent: 3919231 (1975-11-01), Pelosi, Jr., et al.
patent: 4833149 (1989-05-01), Press
patent: 5182291 (1993-01-01), Gubin et al.
patent: 5217986 (1993-06-01), Pomponi et al.
patent: 5352707 (1994-10-01), Pompni et al.
patent: 5580883 (1996-12-01), Goto et al.
patent: 5840746 (1998-11-01), Ducharme et al.
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 5883096 (1999-03-01), Lowe et al.
patent: 5929089 (1999-07-01), Jegham et al.
patent: 6821980 (2004-11-01), Guerry et al.
patent: 0 978 512 (2000-02-01), None
patent: 0 982 300 (2000-03-01), None
patent: 0 982 300 (2000-03-01), None
patent: 2303628 (1997-02-01), None
patent: WO 93/20061 (1993-10-01), None
patent: WO 95/04052 (1995-02-01), None
patent: WO 95/14007 (1995-05-01), None
patent: WO 97/17345 (1997-05-01), None
patent: WO 99/42458 (1999-08-01), None
patent: WO 00/06254 (2000-02-01), None
patent: WO 01/32633 (2001-05-01), None
British Journal of Pharmacology 2001, 132, 1665-1672.
Scribner et al., “1-Aryl-2-pyridyl-3,4-dihydronaphthalenes: Photofluorogeric Ligands for Estrogen Receptor” J. Org. Chem. 1997, 62, 1043-1057.
Schlicker, E., et al.; “The moderate affinity of clozapine at H3 receptors is not shared by its two major metab olites and by structurally related and unrelated atypical neuroleptics”; Naunyn-Schmiedeberg's Arch. Pharmacol.; 1996 353:290-294.
Sheets, Joel J., et al.; “Ketoconazole: A Potent Inhibitor of Cytochrome P-450-Dependent Drug Metabolism in Rat Liver”; Drug Metab. Dispos.; 1984; 12(5):603-606.
Stark, H. et al.; “Developments of histamine H3-receptor antagonists”; Drugs Future; 1996; 21(5):507-520.
Tozer, M.J., et al.: “Histamine H3 receptor antagonists”; Exp. Opin. Ther. Patents; 2000 10:1045-1055.
Walczynski, K. , et al.; “Non-Imidazole Histamine H3 Ligands, Part 2: New 2-Substituted Benzothiazoles as Histamine H3 Antagonists”; Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.); 1999 332:389-398.
Walczynski, K. et al.; “Non-imidazole histamine H3 ligands. Part I. Synthesis of 2-(1-piperazinyl)- and 2-(hexahydro-1H-1,4-diazepin-1-yl)benzoyhiazole derivatives as H3 antagonists with H1 blocking activities”; IL Farmaco; 1999; 54:684-694.
West, R.E. Jr. et al.; “The Profiles of Human and Primate [3H]Na-Methylhistamine Binding Differ From That of Rodents”; Eur. J. Pharmacol.; 1999; 377:233-239.
Yokoyama, H. et al., “Effect of thioperamide, a histamine h3 receptor antagonist, on electrically induced convulsions in mice”; Eur. J. Pharmcol. ; 119 234:129-133.
Albengres, E. et al.; “Systemic Antifungal Agents”; Drug Safety; Feb. 1998; 18(2):83-97.
Ali, S.M. et al., “Design, Synthesis, and Structure-Activity Relationships of Acetylene-Based Histamine H3 Receptor Antagonists”; J. Med. Chem. ; 1999 42:903-909.
Arrang, J.M. et al.; “Auto-inhibition of brain histamine release mediated by a novel class (h3) of histamine receptor” Nature; Apr. 1983; 302:832-837.
Ash, A.S.F. et al; “Receptors Mediating Some Actions of Histamine”; Br. J. Pharmac. Chemother.; 1966 27:427-439.
Back, D.J.; et al; “Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo:evidence for a structure-activity relationship”; Br. J. Pharmacol.; 1985 85:121-126.
Barnes, J.C. et al; “The selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release in vivo”; Soc. Neurosci. Abstr.; 1993 19:1813.
Black, J.W. et al.; “Definition and Antagonism of Histamine H2-receptors”; Nature; Apr. 1972; 236:385-390.
Garbag, M. et al; “S-[2-(4-Imidazolyl)ethyl]Isothiourea, a Highly Specific and Potent Histamine H3 Receptor Agonist”; J. Pharmacol. Exp. Ther.; 1992; 263(1):304-310.
Gilatech, Inc.; “Other News To Note”; Bioworld Today, Mar. 2, 1999, p. 3.
Gilatech, Inc.; “Gilatech's first drug candidate begins phase I human clinical trials”; Gilatech Inc. Press Release; Nov. 5, 1998.
Ichinose, M. et al; “Histamine H3-receptors modulate nonadrenergic noncholinergic neural bronchoconstriction in guinea-pig in vivo”; P.J. Eur. J. Pharmacol; 1989; 174:49-55.
Imamura, M. et al.; “Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release 1,2”; J. Pharmacol, Exp. Ther.; 1994; 271(3):1259-1266.
Kapetanovic, I.M. et al; “Nafimidone, An Imidazole Anticonvulsant, and its Metabolite as Potent Inhibitors of Microsomal Metabolism of Phenytoin and Carbamazepine”; H. J. Drug Metab. Dispos.; 1984 12(5):560-564.
Korte, A. et al; “Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by Na-Methylhistamine”; Biochem. Biophys. Res. Commun.; May 1990; 168(3):979-986.
Krause, M. et al.; “The Histamine H3 Receptor—A Target for New Drugs”; Leurs, R.; Timmerman, H. (Eds.); Elsevier; 1998; 175-196.
Phillips, J. G. et al; “;The Histamine H3 Receptor—A Target for New Drugs”; Leurs, R.; Timmerman, H. (Eds.); Elsevier; 1998; 197-222.
Lavrijsen, K. et al; “Induction Potential of Antifungals Containing an Imidazole or Triazole Moiety”; Biochem. Pharmacol.; 1986 35(11):1867-1878.
Leurs, R. et al; “The medicinal chemistry and therapeutic potentials of ligands of the histamine h3 receptor” Prog. Drug. Res.; 1995; 45:107-165.
Lin, Jian-Sheng et al. “Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat”; Brain Res.; 1990; 523:325-330.
Linney, I.D. et al; “Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists”; J. Med. Chem.; 2000; 43:2362-2370.
Lovenberg, T.W. et al; “Cloning and Functional Expression of the Human Histamine H3 Receptor”; Mol. Pharmacol; 1999 55:1101-1107.
Machidori, H. et al; “Zucker obese rats:defect in brain histamine control of feeding”; Brain Res.; 1992; 590:180-186.
McLeod, R.L. et al; “Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3 Receptor Agonist”; Soc. Neurosci. Abstr.; 1996; 22:2010.
Monti, J.M. et al; “Effects of selective activation or blockade of the histamine h3 receptor on sleep and wakefulness”; Eur. J. Pharmacol.; 1991; 205:283-287.
Morisset, S. et al; “High constitutive activity of native H3 receptors regulates histamine neurons in brain”; Nature; Dec. 2000; 408:860-864.
Oda, Tamaki et al.; “Molecular Cloning and characterization of a Novel Type of Histamine Receptor Preferentially Expressed In Leukocytes”; J. Biol. Chem.; Nov. 2000; 275(47):36781-36786.
Panula, P. et al.; “Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease”Soc. Neurosci. Abstr.; 1995; 21:1977.
Rouleau, A. et al.; “Bioavailability, Antinociceptive and Antiinflammatory Properties of BP 2-94, a Histamine H3 Receptor Agonist Prodrug”; J. Pharmacol. Exp. Ther.; 1997 281(3):1085-1094.
Ganellin, C.R. et al.; “Synthesis of Potent Non-imidazole Histamine H3-Receptor Antagonists”; Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.); 1998 331:395-404.
Meier, G. et al.; “Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists”; Eur. J. Pharm. Sci.; 2001; 13:249-259.
International Search Report for PCT/US 01/24655 dated Apr. 18, 2002.
Green, Protective Groups in Organic Synthesis (1981).
Stark et al., “General Construction Pattern of Histamine H3-Receptor Antagonists: Change of a Paradigm”, Bioorganic & Medicinal Chemistry Letters, vol. 8 (1998) pp. 2011-2016.
West, Jr. et al., &
Apodaca Richard
Carruthers Nicholas I.
Dvorak Curt A.
Rudolph Dale A.
Shah Chandravadan R.
Ortho-McNeil Pharmaceutical , Inc.
Saeed Kamal A.
LandOfFree
Non-imidazole aryloxyalkylamines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-imidazole aryloxyalkylamines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-imidazole aryloxyalkylamines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3729103